Skip to navigation Skip to content

Treating PPMS

Share

Modifying the Disease Course

One medication -- Ocrevus® (ocrelizumab) -- has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of primary-progressive MS (PPMS) as well as for relapsing forms of MS, which include clinically isolated syndrome, relapsing-remitting disease (RRMS) and active secondary progressive disease (SPMS with relapses).  The disease-modifying therapies work primarily by reducing inflammation in the central nervous system (CNS); they do not work as well in a disease course that is characterized by nerve degeneration rather than inflammation. For this reason, they have not been shown to be effective in progressive forms of the disease unless a person demonstrates relapses or MRI activity caused by inflammation.

Several of these agents, including Copaxone® and an experimental drug called Rituxan, have been studied in PPMS, but unfortunately without a positive effect on progression. There are several clinical trials either recently completed or ongoing for progressive forms of MS and some are for PPMS. Read more about clinical trials in MS.

In addition to treatment with a disease-modifying therapy, there are other symptom management and rehabilitation strategies that people with PPMS and their healthcare teams can use to manage the disease.

MANAGING SYMPTOMS

Regardless of the course of MS a person is experiencing, proactive symptom management is essential to maintaining comfort and productivity, and enhancing quality of life.

REHABILITATION

Rehabilitation specialists have an important role from the time of diagnosis helping people function optimally in spite of their MS, including enhancing mobility and promoting safety and independence.

Share

Your input is important!

We believe that people affected by MS live better lives when they're connected.  To help us provide you with the best resources, support and information, please provide your feedback in a short survey.
Take the survey